<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73835">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01866943</url>
  </required_header>
  <id_info>
    <org_study_id>11-253</org_study_id>
    <nct_id>NCT01866943</nct_id>
  </id_info>
  <brief_title>Role of Topical Tranexamic Acid in Total Hip Arthroplasty</brief_title>
  <acronym>TXA</acronym>
  <official_title>Role of Topical Tranexamic Acid in Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Shore Long Island Jewish Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>North Shore Long Island Jewish Health System</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total hip arthroplasty (THA) is a procedure associated with perioperative blood loss,
      requiring blood transfusions in some patients. The major cause of this blood loss is due to
      surgical trauma that induces the clotting cascade and fibrinolysis. Several previous studies
      and meta-analyses have shown that tranexamic acid is an effective antifibrinolytic agent
      that reduces blood loss in a variety of situations. Tranexamic acid given in an intravenous
      form has been extensively studied and shown to be efficacious in cardiothoracic, spine
      surgical procedures as well as total knee arthroplasty (TKA) and THA. Similarly, topical
      tranexamic acid has been associated with decreased blood loss in cardiac surgeries as well.
      Recently, results from a prospective randomized study on the topical use of tranexamic acid
      in total knee arthroplasty found it to be effective for reducing postoperative blood loss.
      Taking all of the above into consideration we have proposed a study to evaluate effects of
      topical application of tranexamic acid on postoperative blood loss and blood transfusion on
      patients undergoing total hip arthroplasty. The aim of this study is to evaluate the
      efficacy of the topical application of tranexamic acid on blood loss in patients undergoing
      a primary unilateral total hip arthroplasty.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Estimated Blood Loss</measure>
    <time_frame>Pre Op, Post Op Day 1 and Post Op Day 2</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Estimated Blood Loss defined as Pre Op Hgb mins the Post Op Day two Hgb.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mid Thigh Circumference</measure>
    <time_frame>Pre Op, 2wk Post op, 6wk Post op</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of the thigh at the half way point between the prominence of the greater trochanter and the lateral epicondyle of the femur.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Harris Hip Scores</measure>
    <time_frame>Pre Op, 2wk, and 6wk</time_frame>
    <safety_issue>No</safety_issue>
    <description>Standardized questionnaire as a measurement of clinical function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Post Operative Blood Loss</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline plus 1.5 g (100 mg/mL)Tranexamic Acid is applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Tranexamic Acid 1.5 g (100 mg/mL)in 100cc normal saline is applied topically to the wound for 5 minutes time then suctioned and the skin closed.  The control group receives just normal saline and no drug.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years of age.

          -  Male or female.

          -  Degenerative joint disease of hip joint.

          -  Primary uncemented total hip arthroplasty.

          -  Willingness to participate in the study, follow up at regular intervals

        Exclusion Criteria:

          -  Known allergy to tranexamic acid

          -  History of any acquired disturbances of color vision

          -  Preoperative anemia on basis of pre-operative lab work up (a hemoglobin value of &lt;11
             g/dL in females and &lt;12 g/dL in males)

          -  History of previous myocardial infarction

          -  History of arterial or venous thromboembolic disease

          -  History of fibrinolytic disorders requiring intraoperative antifibrinolytic
             treatment, coagulopathy in the past and/or as identified by a preoperative platelet
             count of &lt;150,000/mm3, an international normalized ratio of &gt;1.5, or a prolonged
             partial thromboplastin time

          -  Pregnancy (h/o any missed menstrual periods in a women of reproductive age group)

          -  Breastfeeding

          -  Refusal of blood products

          -  Preoperative use of anticoagulant therapy within five days before surgery

          -  Medical issues that may pose complications for surgery and would disqualify patient
             for surgery regardless of clinical trial (e.g. renal and hepatic failure)

          -  Major comorbidities (e.g. severe ischemic heart disease )

          -  Severe pulmonary disease

          -  Preoperative blood donation

          -  Participation in another clinical trial involving pharmaceutical drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>North Shore Long Island Jewish Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tsutsumimoto T, Shimogata M, Ohta H, Yui M, Yoda I, Misawa H. Tranexamic acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study. Spine (Phila Pa 1976). 2011 Nov 1;36(23):1913-8. doi: 10.1097/BRS.0b013e3181fb3a42.</citation>
    <PMID>21289587</PMID>
  </reference>
  <reference>
    <citation>Elwatidy S, Jamjoom Z, Elgamal E, Zakaria A, Turkistani A, El-Dawlatly A. Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study. Spine (Phila Pa 1976). 2008 Nov 15;33(24):2577-80.</citation>
    <PMID>19011538</PMID>
  </reference>
  <reference>
    <citation>Bednar DA, Bednar VA, Chaudhary A, Farrokhyar F. Tranexamic acid for hemostasis in the surgical treatment of metastatic tumors of the spine. Spine (Phila Pa 1976). 2006 Apr 15;31(8):954-7. Erratum in: Spine. 2006 Jul 15;31(16):1866. Farroukhyar, Forough [corrected to Farrokhyar, Forough].</citation>
    <PMID>16622388</PMID>
  </reference>
  <reference>
    <citation>Eubanks JD. Antifibrinolytics in major orthopaedic surgery. J Am Acad Orthop Surg. 2010 Mar;18(3):132-8. Review.</citation>
    <PMID>20190103</PMID>
  </reference>
  <reference>
    <citation>Charoencholvanich K, Siriwattanasakul P. Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial. Clin Orthop Relat Res. 2011 Oct;469(10):2874-80. doi: 10.1007/s11999-011-1874-2. Epub 2011 Apr 22.</citation>
    <PMID>21512813</PMID>
  </reference>
  <reference>
    <citation>Ishida K, Tsumura N, Kitagawa A, Hamamura S, Fukuda K, Dogaki Y, Kubo S, Matsumoto T, Matsushita T, Chin T, Iguchi T, Kurosaka M, Kuroda R. Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty. Int Orthop. 2011 Nov;35(11):1639-45. doi: 10.1007/s00264-010-1205-3. Epub 2011 Jan 21.</citation>
    <PMID>21253725</PMID>
  </reference>
  <reference>
    <citation>Johansson T, Pettersson LG, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients. Acta Orthop. 2005 Jun;76(3):314-9.</citation>
    <PMID>16156456</PMID>
  </reference>
  <reference>
    <citation>Molloy DO, Archbold HA, Ogonda L, McConway J, Wilson RK, Beverland DE. Comparison of topical fibrin spray and tranexamic acid on blood loss after total knee replacement: a prospective, randomised controlled trial. J Bone Joint Surg Br. 2007 Mar;89(3):306-9.</citation>
    <PMID>17356139</PMID>
  </reference>
  <reference>
    <citation>Niskanen RO, Korkala OL. Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis. Acta Orthop. 2005 Dec;76(6):829-32.</citation>
    <PMID>16470437</PMID>
  </reference>
  <reference>
    <citation>Rajesparan K, Biant LC, Ahmad M, Field RE. The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. J Bone Joint Surg Br. 2009 Jun;91(6):776-83. doi: 10.1302/0301-620X.91B6.22393.</citation>
    <PMID>19483232</PMID>
  </reference>
  <reference>
    <citation>Abrishami A, Chung F, Wong J. Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis. Can J Anaesth. 2009 Mar;56(3):202-12. Epub 2009 Feb 12. Review.</citation>
    <PMID>19247741</PMID>
  </reference>
  <reference>
    <citation>Abul-Azm A, Abdullah KM. Effect of topical tranexamic acid in open heart surgery. Eur J Anaesthesiol. 2006 May;23(5):380-4. Epub 2006 Jan 27.</citation>
    <PMID>16438759</PMID>
  </reference>
  <reference>
    <citation>De Bonis M, Cavaliere F, Alessandrini F, Lapenna E, Santarelli F, Moscato U, Schiavello R, Possati GF. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg. 2000 Mar;119(3):575-80.</citation>
    <PMID>10694619</PMID>
  </reference>
  <reference>
    <citation>Fawzy H, Elmistekawy E, Bonneau D, Latter D, Errett L. Can local application of Tranexamic acid reduce post-coronary bypass surgery blood loss? A randomized controlled trial. J Cardiothorac Surg. 2009 Jun 18;4:25.</citation>
    <PMID>19538741</PMID>
  </reference>
  <reference>
    <citation>Hanif M, Nourei SM, Dunning J. Does the use of topical tranexamic acid in cardiac surgery reduce the incidence of post-operative mediastinal bleeding? Interact Cardiovasc Thorac Surg. 2004 Dec;3(4):603-5.</citation>
    <PMID>17670322</PMID>
  </reference>
  <reference>
    <citation>Wong J, Abrishami A, El Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R, Syed KA, Muhammad Ovais Hasan S, De Silva Y, Chung F. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am. 2010 Nov 3;92(15):2503-13. doi: 10.2106/JBJS.I.01518.</citation>
    <PMID>21048170</PMID>
  </reference>
  <reference>
    <citation>Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br. 2011 Jan;93(1):39-46. doi: 10.1302/0301-620X.93B1.24984. Review.</citation>
    <PMID>21196541</PMID>
  </reference>
  <reference>
    <citation>Zufferey P, Merquiol F, Laporte S, Decousus H, Mismetti P, Auboyer C, Samama CM, Molliex S. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology. 2006 Nov;105(5):1034-46. Review.</citation>
    <PMID>17065899</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>May 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>North Shore Long Island Jewish Health System</investigator_affiliation>
    <investigator_full_name>Jose Rodriguez, MD</investigator_full_name>
    <investigator_title>Chieff Of Adult Reconstruction, Department of Orthopedics</investigator_title>
  </responsible_party>
  <keyword>Blood Loss</keyword>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Total Hip Arthroplasty</keyword>
  <keyword>Post Op</keyword>
  <keyword>Post Operative</keyword>
  <keyword>Prevent Post Operative Blood Loss</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
